Paul R. Kirchgraber - 01 Nov 2021 Form 4 Insider Report for LABORATORY CORP OF AMERICA HOLDINGS (LH)

Role: CEO, Covance Drug Development
Signature: /s/ Sandra van der Vaart, Attorney-in-Fact for Paul R. Kirchgraber
Issuer symbol: LH
Transactions as of: 01 Nov 2021
Net transactions value: -$259,324
Form type: 4
Filing time: 03 Nov 2021, 11:47:40 UTC
Previous filing: 10 May 2021
Next filing: 04 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LH	Common Stock	Options Exercise		+2,007	+26%		9,851	01 Nov 2021	Direct	F1
transaction	LH	Common Stock	Tax liability	$259,324	-898	-9.1%	$288.78	8,953	01 Nov 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LH	Restricted Stock Unit	Options Exercise	$0	-2,007	-30%	$0.000000	4,774	01 Nov 2021	Common Stock	2,007		Direct	F1, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
F2	Stock withholding to satisfy tax withholding obligations.
F3	The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 1, 2020.
F4	This number reflects the aggregate number of Restricted Stock Units held by the reporting person.